Articles by Erin Slifka

The approval of the Biogen drug, which has the molecular name aducanumab and will be sold as Aduhelm, marked a watershed in Alzheimer’s drug research after billions of dollars in investment.

The firm agreed to pay a fine of nearly $270 million as part of a settlement with French regulators of one of the first antitrust cases globally to allege the tech company abused its leading role in the digital advertising sector.

Buffeted by political upheaval, a crackdown by mainland China and the pandemic, global companies are heading for rival cities such as Singapore and Shanghai.

Private-equity firms, tasked with putting over a trillion dollars to work, had largely shied away from the biggest deals—until now.

Many governments are likely to wait and see what others, especially a divided U.S. Congress, will do to put the deal into effect.

More administrators took hazard pay than the state previously acknowledged, records show.

The latest salvos in China’s campaign against its tech companies make one thing clear: Jack Ma’s businesses aren’t the only ones under the regulatory microscope.